InspireMD (Nasdaq: NSPR) announced FDA approval for its flagship CGuard Prime Carotid Stent System, a next-generation mesh-covered stent developed to prevent stroke by treating carotid…
June 24, 2025
May 19, 2025
Skye Bioscience and Arecor Partner to Advance High-Concentration Formulation of Obesity Drug Candidate
The clinical-stage biotechnology company targeting novel treatments for obesity and metabolic disorders Skye Bioscience, Inc. (Nasdaq: SKYE), has entered a formulation development collaboration with Arecor…
A pioneer in adult stem cell therapies for neurodegenerative diseases BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), has received clearance from the U.S. Food and Drug…
Moleculin Biotech (NASDAQ: MBRX) has taken a major step forward in its development of Annamycin, a next-generation cancer therapy, by receiving authorization from the European…
The up-and-coming precision diagnostics biotech company, Oncocyte Corporation (Nasdaq: OCX), announced significant progress toward regulatory authorization of its organ transplant rejection test kit, including central…
March 07, 2025
Plus Therapeutics’ Rhenium (186Re) Obisbemeda Shows Encouraging Survival Benefits in Glioblastoma Trial, Shares Up ~19%
Plus Therapeutics’ Rhenium (186Re) Obisbemeda Shows Encouraging Survival Benefits in Glioblastoma Trial, Shares Up ~19% Plus Therapeutics (PSTV) has announced the publication of promising Phase…
Mesoblast (Nasdaq: MESO; ASX: MSB) is moving forward with the U.S. commercial launch of Ryoncil® (remestemcel-L), the first and only FDA-approved mesenchymal stromal cell (MSC)…
Bio-Path Holdings NASDAQ: BPTH, Inc., a pioneering biotech firm, has announced promising results from preclinical studies of its latest development, BP1001-A, a targeted nucleic acid…
December 19, 2024
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Third Netherton Syndrome Clinical Study, A First of Its Kind
The rare and orphan disease focused clinical stage pharmaceutical company Quoin Pharmaceuticals (Nasdaq: QNRX) has announced FDA clearance to initiate a new QRX003 Netherton Syndrome…
December 12, 2024
Aditxt Subsidiary Adimune Completes Preclinical Studies for ADI-100, Advances Toward Human Clinical Trials
Immune Modulation Gains Momentum with Industry Focus and High-Value Collaborations Aditxt, Inc. (NASDAQ: ADTX) announced that its subsidiary, Adimune, Inc., has successfully completed all preclinical…
November 19, 2024
Former Biotech CEO and Trump Appointee Vivek Ramaswamy Slams FDA Bureaucracy for Stifling Innovation and Driving Up Drug Costs
If former biotech entrepreneur Vivek Ramaswamy has his way, things will look a lot different at the FDA in the next four years. Ramaswamy and…
October 21, 2024
Trevi Therapeutics Completes Enrollment for Phase 2a Chronic Cough Trial; Topline Results Expected Q1 2025
Trevi Therapeutics (Nasdaq: TRVI) has completed enrollment for its Phase 2a trial evaluating Haduvio™ (oral nalbuphine ER) for the treatment of refractory chronic cough (RCC)….